What is Rozacrème 0.75%?
Rozacrème 0.75% is used to treat bacterial infections in different areas of the body. The extended-release tablets are used to treat women with vaginal infections (bacterial vaginosis).
Rozacrème 0.75% belongs to the class of medicines known as antibiotics. It works by killing bacteria or preventing their growth. However, Rozacrème 0.75% will not work for colds, flu, or other virus infections.
Rozacrème 0.75% is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Rozacrème 0.75% is used in certain patients with the following medical conditions:
- Clostridium difficile diarrhea or colitis (antibiotic-associated colitis).
- Crohn's disease (inflammatory bowel disease).
- Gastritis or stomach ulcers due to Helicobacter pylori.
- Giardiasis (parasite infection in the intestines).
Rozacrème 0.75% indications
Symptomatic Trichomoniasis. Rozacrème 0.75% Capsules USP 375 mg are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).
Asymptomatic Trichomoniasis. Rozacrème 0.75% Capsules USP 375 mg are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.
Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with Rozacrème 0.75% in cases of reinfection.
Amebiasis. Rozacrème 0.75% Capsules USP 375 mg are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess.
In amebic liver abscess, Rozacrème 0.75% Capsules USP 375 mg therapy does not obviate the need for aspiration or drainage of pus.
Anaerobic Bacterial Infections. Rozacrème 0.75% Capsules USP 375 mg are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Rozacrème 0.75% therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to Rozacrème 0.75% Capsules USP 375 mg.
INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, or Peptostreptococcus species.
SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, or Fusobacterium species.
GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, or Fusobacterium species.
BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group or Clostridium species.
BONE AND JOINT INFECTIONS (as adjunctive therapy) caused by Bacteroides species including the B. fragilis group.
CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group.
LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group.
ENDOCARDITIS caused by Bacteroides species including the B. fragilis group.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Rozacrème 0.75% Capsules USP 375 mg and other antibacterial drugs, Rozacrème 0.75% Capsules USP 375 mg should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Rozacrème 0.75%?
Use Rozacrème 0.75% cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Wash and completely dry the affected area. Be sure the area is completely dry before applying Rozacrème 0.75% cream.
- Apply a thin layer of Rozacrème 0.75% cream to the affected area. Gently rub the medicine in until it is evenly distributed.
- Wash your hands immediately after using Rozacrème 0.75% cream.
- You may apply cosmetics after you use Rozacrème 0.75% cream. If you are using the lotion, wait 5 minutes after you use Rozacrème 0.75% cream before you apply cosmetics so that the lotion has time to dry.
- Use Rozacrème 0.75% cream on a regular schedule to get the most benefit from it. Using it at the same time(s) each day will help you remember to use it.
- Continue to use Rozacrème 0.75% cream even if your condition improves, unless a doctor tells you otherwise. Do not miss any doses.
- If you miss a dose of Rozacrème 0.75% cream, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Rozacrème 0.75% cream.
Uses of Rozacrème 0.75% in details
Rozacrème 0.75% is an antibiotic that is used to treat a wide variety of infections. It works by stopping the growth of certain bacteria and parasites.
This antibiotic treats only certain bacterial and parasitic infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.
Rozacrème 0.75% may also be used with other medications to treat certain stomach/intestinal ulcers caused by a bacteria (H. pylori).
How to use Rozacrème 0.75%
Take this medication by mouth as directed by your doctor. To prevent stomach upset, take this medication with food or a full glass of water or milk. The dosage is based on your medical condition and response to treatment.
Antibiotics work best when the amount of medicine in your body is kept at a constant level. Take this drug at evenly spaced intervals.
Continue to take this medication until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may result in a return of the infection.
Tell your doctor if your condition lasts or gets worse.
Rozacrème 0.75% description
Each 100 mL contains Metronidazole USP 500 mg, sodium chloride USP 0.72% w/v, water for injection USP as needed.
Rozacrème 0.75% injection, USP is a parenteral dosage form of the synthetic antibacterial agent 1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole. The empirical formula is C6H9N3O3 and the molecular weight is 171.15.
Rozacrème 0.75% injection, USP in 100 mL is a sterile, nonpyrogenic, iso-osmotic, buffered solution of 500 mg Rozacrème 0.75%, USP, 790 mg sodium chloride, USP, 47.6 mg dried dibasic sodium phosphate, USP and 22.9 mg anhydrous citric acid, USP. Rozacrème 0.75% injection, USP has an osmolarity of 310 mOsmol/L (calc) and a pH of 5.5 (4.5 to 7).
Rozacrème 0.75% dosage
Rozacrème 0.75% ER Dosage
Generic name: Rozacrème 0.75% 750mg
Dosage form: tablet, film coated, extended release
See also:
- Rozacrème 0.75% tablet, film coated
- Rozacrème 0.75% 375 Capsules capsule
- Rozacrème 0.75% Injection injection, solution
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Bacterial Vaginosis
750 mg once daily by mouth for seven consecutive days.
Rozacrème 0.75% ER 750 mg tablets should be taken under fasting conditions, at least one hour before or two hours after meals. The optimum extended-release characteristics of Rozacrème 0.75% ER 750 mg are obtained when the drug is taken under fasting conditions.
Rozacrème 0.75% ER tablets should not be split, chewed, or crushed.
Dosage Adjustments
Patients Undergoing Hemodialysis
Hemodialysis removes significant amounts of Rozacrème 0.75% and its metabolites from systemic circulation. The clearance of Rozacrème 0.75% will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of Rozacrème 0.75% cannot be separated from a hemodialysis session, supplementation of Rozacrème 0.75% dosage following the hemodialysis session should be considered, depending on the patient's clinical situation.
More about Rozacrème 0.75% ER (Rozacrème 0.75%)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- En Espanol
- 6 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Rozacrème 0.75% ER extended-release tablets
- Rozacrème 0.75% ER
- Rozacrème 0.75% ER (Advanced Reading)
- Other brands: Metro
Professional resources
- Rozacrème 0.75% ER (FDA)
- Rozacrème 0.75% Hydrochloride (AHFS Monograph)
Other formulations
- Rozacrème 0.75%
- Rozacrème 0.75% IV
- Rozacrème 0.75% 375
Related treatment guides
- Bacterial Vaginitis
- Balantidium coli
- Dientamoeba fragilis
- Nongonococcal Urethritis
- STD Prophylaxis
Rozacrème 0.75% interactions
See also:
What other drugs will affect Rozacrème 0.75%?
Simultaneous administration of Zol with:
Rozacrème 0.75% side effects
See also:
What are the possible side effects of Rozacrème 0.75%?
In a controlled clinical trial, safety data from 141 patients who used Rozacrème 0.75% Lotion
Topical Lotion (n=71), or the lotion vehicle (n=70), twice daily and experienced a local cutaneous adverse event which may or may not have been related to the treatments include: local allergic reaction, Rozacrème 0.75%
Topical Lotion 2 (3%), lotion vehicle 0; contact dermatitis, Rozacrème 0.75% Lotion
Topical Lotion 2 (3%), lotion vehicle 1 (1%); pruritus, Rozacrème 0.75% Lotion
Topical Lotion 1 (1%), lotion vehicle 0; skin discomfort (burning and stinging), Rozacrème 0.75% Lotion
Topical Lotion 1 (1%), lotion vehicle 2 (3%); erythema, Rozacrème 0.75% Lotion
Topical Lotion 4 (6%), lotion vehicle 0; dry skin, Rozacrème 0.75% Lotion
Topical Lotion 0, lotion vehicle 1 (1%); and worsening of rosacea, Rozacrème 0.75% Lotion
Topical Lotion 1 (1%), lotion vehicle 7 (10%).
The following additional adverse experiences have been reported with the topical use of Rozacrème 0.75%: skin irritation, transient redness, metallic taste, tingling or numbness of extremities, and nausea.
Rozacrème 0.75% contraindications
See also:
What is the most important information I should know about Rozacrème 0.75%?
Hypersensitivity
Rozacrème 0.75% Capsules 375 mg are contraindicated in patients with a prior history of hypersensitivity to Rozacrème 0.75% or other nitroimidazole derivatives.
In patients with trichomoniasis, Rozacrème 0.75% Capsules 375 mg are contraindicated during the first trimester of pregnancy.
Psychotic Reaction with Disulfiram
Use of oral Rozacrème 0.75% is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. Do not administer Rozacrème 0.75% to patients who have taken disulfiram within the last two weeks.
Interaction with Alcohol
Use of oral Rozacrème 0.75% is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. Discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with Rozacrème 0.75%.
Active ingredient matches for Rozacrème 0.75%:
Metronidazole in France.
List of Rozacrème 0.75% substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Rozacrème (France) | |
| Cream; Topical; Metronidazole 0.75% (Biorga) | |
| RozacrГЁme (France) | |
| Rozagel (France) | |
| Gel; Local; Metronidazole 0.75% (Biorga) | |
| Rozagel 0.75% (France) | |
| Rozamet (Bosnia & Herzegowina, Croatia (Hrvatska), Georgia, Russian Federation, Serbia, Slovenia) | |
| Cream; Topical; Metronidazole 1% | |
| Rozamet 1% (Bosnia & Herzegowina) | |
| Rozek (Venezuela) | |
| Rozex 0.75% (France) | |
| Rozex 7.5mg/g (Hungary) | |
| Rozex Cream (United Kingdom) | |
| Rozex Gel (United Kingdom) | |
| Rozex Topical | |
| Rubrimet (Chile) | |
| Rupezol (Argentina) | |
| Sabax Metronidazole (South Africa) | |
| SABS (Taiwan) | |
| SABS 5 mg/1 mL x 1 Bottle x 100 mL (Sarthak Biotech Pvt. Ltd.) | |
| Sabs 5 mg/1 mL x 100 mL (Sarthak Biotech Pvt. Ltd.) | |
| Sabs 5 mg/1 mL x 300 mL (Sarthak Biotech Pvt. Ltd.) | |
| Sabs Skin 50 ml Lotion (Sarthak Biotech Pvt. Ltd.) | $ 0.18 |
| Sabs Skin 100 ml Lotion (Sarthak Biotech Pvt. Ltd.) | $ 0.34 |
| Samonil (Mexico) | |
| Sanatrichom | |
| Sandoz Metronidazole (South Africa) | |
| Sanofi Pasteur Metronidazole (Philippines) | |
| Santon (Taiwan) | |
| Santon 500 mg x 1000's | |
| Sarnomet | |
| Sarnomet 30 ml Suspension (Sarthak Biotech Pvt. Ltd.) | $ 0.05 |
| Satric (India) | |
| Tablet; Oral; Metronidazole 250 mg (Zytras Life Sciences) | |
| Tablet; Oral; Metronidazole 500 mg (Zytras Life Sciences) | |
| 100 mg x 100's (Zytras Life Sciences) | $ 2.89 |
| Satric 100mg TAB / 100 (Zytras Life Sciences) | $ 2.89 |
| Satric 100 mg Tablet (Zytras Life Sciences) | $ 0.03 |
| SATRIC tab 100 mg x 10's (Zytras Life Sciences) | $ 0.29 |
| Satric-500 | |
| Say O Flox M | |
| Say O Flox M 30 ml Suspension (Sayona Medicare Pvt Ltd) | $ 0.06 |
| Seltrozol (Philippines) | |
| Septigard (India) | |
| Septigard Skin 10 gm Ointment (Vanguard Laboratories) | $ 0.31 |
| SEPTIGARD 1%/5% OINTMENT 1 tube / 15 GM ointment each (Vanguard Laboratories) | $ 0.80 |
| SEPTIGARD DUSTING POWDER 1 packet / 10 GM dusting powder each (Vanguard Laboratories) | $ 0.32 |
| SEPTIGARD OINTMENT 1 tube / 10 GM ointment each (Vanguard Laboratories) | $ 0.42 |
| SEPTIGARD SOLUTION 1 bottle / 30 ML solution each (Vanguard Laboratories) | $ 0.35 |
| SEPTIGARD oint 10g (Vanguard Laboratories) | $ 0.31 |
| Septigard 1%/5% Ointment (Vanguard Laboratories) | $ 0.05 |
See 2352 substitutes for Rozacrème 0.75% | |
References
- DailyMed. "BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "metronidazole". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "metronidazole". http://www.drugbank.ca/drugs/DB00916 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Rozacrème 0.75% are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Rozacrème 0.75%. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
